| Not Yet Recruiting | Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreate NCT07520123 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Not Yet Recruiting | A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Inte NCT07537387 | xieqing | — |
| Not Yet Recruiting | Adaptability of an Undetectable = Untransmissible Model for HBV NCT07449091 | NYU Langone Health | — |
| Not Yet Recruiting | A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infe NCT03038802 | Vaxine Pty Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic He NCT07345624 | Qing-Lei Zeng | Phase 4 |
| Not Yet Recruiting | Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepa NCT07345611 | Qing-Lei Zeng | Phase 4 |
| Not Yet Recruiting | Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A NCT07258251 | The Task Force for Global Health | Phase 4 |
| Recruiting | SA1211 Injection Phase 1 Study NCT07275918 | Suzhou Siran Biotechnology Co.,Ltd. | Phase 1 |
| Active Not Recruiting | A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection NCT07245953 | Suzhou HepaThera Biotech Co., Ltd. | Phase 2 |
| Recruiting | TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B NCT04843852 | University of Maryland, Baltimore | Phase 1 |
| Active Not Recruiting | A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B NCT07135349 | Shanghai Argo Biopharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis NCT07120750 | Shenzhen Third People's Hospital | — |
| Recruiting | A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chroni NCT07307586 | Zhigang Ren | Phase 3 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB NCT07137910 | Ausper Biopharma Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB- NCT07146100 | Ausper Biopharma Co., Ltd. | — |
| Not Yet Recruiting | Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of C NCT07071636 | Shenzhen Third People's Hospital | Phase 4 |
| Active Not Recruiting | Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUS NCT07246889 | Ausper Biopharma Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB NCT07095855 | Shanghai Zhimeng Biopharma, Inc. | Phase 3 |
| Recruiting | To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatit NCT07090759 | Fujian Akeylink Biotechnology Co., Ltd. | Phase 3 |
| Withdrawn | A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infecte NCT06990776 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B NCT07203118 | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chron NCT06993480 | Ausper Biopharma Co., Ltd. | Phase 2 |
| Enrolling By Invitation | TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate NCT06513286 | Michael Hoelscher | Phase 1 / Phase 2 |
| Recruiting | Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance NCT07257562 | First Affiliated Hospital of Fujian Medical University | — |
| Active Not Recruiting | A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs NCT07069569 | Ausper Biopharma Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus NCT06989788 | AstriVax Therapeutics | Phase 1 |
| Not Yet Recruiting | A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B NCT06926647 | Beijing 302 Hospital | — |
| Not Yet Recruiting | Effects of Peginterferon Consolidation Therapy on Hepatic cccDNA Dynamics in CHB Patients Achieving Clinical C NCT06920329 | Xiamen Hospital of Traditional Chinese Medicine | N/A |
| Not Yet Recruiting | Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negati NCT06900166 | Huashan Hospital | Phase 4 |
| Recruiting | VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B NCT06092333 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Recruiting | Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection NCT06966908 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Recruiting | MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B NCT06779058 | Shengjing Hospital | — |
| Recruiting | HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients NCT06885710 | Changhai Hospital | Phase 1 |
| Active Not Recruiting | A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection NCT07183306 | Suzhou HepaThera Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B NCT06745973 | Epigenic Therapeutics, Inc | EARLY_Phase 1 |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B NCT06829329 | Ausper Biopharma Co., Ltd. | Phase 2 |
| Active Not Recruiting | Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection NCT06706310 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients NCT06661148 | Epigenic Therapeutics, Inc | Phase 1 |
| Recruiting | Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B NCT06671093 | Tune Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-W NCT06627608 | Chinese University of Hong Kong | — |
| Active Not Recruiting | Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection NCT06638320 | Tam Anh Research Institute | — |
| Recruiting | Research on Clinical Recovery and Maintenance Strategies for CHB NCT06803368 | Beijing Municipal Administration of Hospitals | N/A |
| Not Yet Recruiting | Hepatitis Inequalities Study NCT06596213 | Chinese University of Hong Kong | — |
| Not Yet Recruiting | Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB NCT06616103 | Seoul National University Hospital | — |
| Recruiting | Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of NCT06696664 | Minghui Li | — |
| Recruiting | Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B NCT06154278 | University of Maryland, Baltimore | Phase 2 |
| Terminated | A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 NCT06162299 | Yisheng Biopharma (Singapore) Pte. Ltd. | Phase 1 |
| Recruiting | Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients NCT06457477 | Beijing 302 Hospital | N/A |
| Recruiting | A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injec NCT06425341 | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic He NCT06384131 | Assembly Biosciences | Phase 1 |
| Recruiting | Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project. NCT07169656 | The First Affiliated Hospital of Zhengzhou University | — |
| Active Not Recruiting | The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients NCT06357806 | Beijing 302 Hospital | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects W NCT05828745 | Shanghai Zhimeng Biopharma, Inc. | Phase 1 |
| Not Yet Recruiting | The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B NCT05705141 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Completed | Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial NCT06221605 | Wecare Probiotics Co., Ltd. | N/A |
| Recruiting | SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus NCT06364930 | Chinese University of Hong Kong | Phase 4 |
| Recruiting | A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nu NCT06566248 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Recruiting | Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristic NCT06047093 | Hospices Civils de Lyon | N/A |
| Recruiting | Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study） NCT06323681 | Qing XIe | N/A |
| Recruiting | Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance NCT06779864 | Beijing Friendship Hospital | — |
| Unknown | Population-wide Research for HBV-related Liver Diseases in Maoming City NCT06184347 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate NCT05727267 | Universitätsklinikum Hamburg-Eppendorf | Phase 1 |
| Active Not Recruiting | Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients NCT07204236 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | EARLY_Phase 1 |
| Recruiting | Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoh NCT06368882 | First Affiliated Hospital of Wenzhou Medical University | Phase 4 |
| Unknown | Impact of Hepatitis B Virus Genotype on Treatment Response in Children With Chronic Hepatitis B NCT06289725 | Ly Hoa Anh Minh | — |
| Recruiting | A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of NCT06263959 | Fujian Akeylink Biotechnology Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatmen NCT06150014 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults NCT06777173 | Beijing Ditan Hospital | N/A |
| Unknown | A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects NCT06085053 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Gut Microbiome in People Living With HIV and HBV NCT06130137 | Kangbuk Samsung Hospital | — |
| Completed | A Study of RBD1016 in CHB Participants NCT05961098 | Suzhou Ribo Life Science Co. Ltd. | Phase 2 |
| Recruiting | A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Su NCT05769816 | The Second Affiliated Hospital of Chongqing Medical University | Phase 2 |
| Recruiting | A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Su NCT05771402 | The Second Affiliated Hospital of Chongqing Medical University | Phase 2 |
| Active Not Recruiting | Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic NCT06070051 | Virion Therapeutics | Phase 1 |
| Completed | Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. NCT05960240 | Arbutus Biopharma Corporation | Phase 1 |
| Unknown | Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 NCT05841095 | Erasmus Medical Center | Phase 1 / Phase 2 |
| Enrolling By Invitation | Chronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention. NCT05956379 | National Taiwan University Hospital | N/A |
| Completed | A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Ar NCT05905458 | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 |
| Unknown | Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects NCT06280534 | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Phase 1 |
| Completed | Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatit NCT06744686 | Suzhou HepaThera Biotech Co., Ltd. | Phase 1 |
| Completed | Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis NCT05871749 | So Yeon Kim | — |
| Active Not Recruiting | Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic H NCT05905731 | Beijing 302 Hospital | Phase 1 |
| Unknown | A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance NCT06313255 | Qilu Hospital of Shandong University | — |
| Unknown | Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration NCT05808374 | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Pa NCT05763576 | Hoffmann-La Roche | Phase 1 |
| Terminated | To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B NCT05760781 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 |
| Terminated | Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B NCT05760703 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 |
| Completed | Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic He NCT05770895 | Gilead Sciences | Phase 1 |
| Unknown | The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment NCT05755776 | The Second Affiliated Hospital of Chongqing Medical University | — |
| Completed | A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B NCT05717686 | AusperBio Therapeutics Inc. | Phase 1 |
| Unknown | Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer NCT05721300 | Zhongshan Hospital (Xiamen), Fudan University | N/A |
| Completed | Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets NCT05637541 | Fujian Akeylink Biotechnology Co., Ltd. | Phase 2 |
| Completed | Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B NCT06573190 | Yaşar Bayındır, MD | — |
| Unknown | Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis NCT05786963 | Beijing Friendship Hospital | — |
| Active Not Recruiting | Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B NCT05793268 | E-DA Hospital | N/A |
| Active Not Recruiting | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) NCT05630807 | GlaxoSmithKline | Phase 3 |
| Active Not Recruiting | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) NCT05630820 | GlaxoSmithKline | Phase 3 |
| Recruiting | Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase NCT05661786 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Completed | This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive H NCT06746311 | Suzhou HepaThera Biotech Co., Ltd. | Phase 1 |
| Completed | A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects NCT05569941 | Assembly Biosciences | Phase 1 |
| Terminated | A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Do NCT05561530 | Aligos Therapeutics | Phase 1 |
| Completed | Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Su NCT05310487 | Yangshengtang Co., Ltd | Phase 1 |
| Active Not Recruiting | Efficacy of VTP-300 in Chronic Hepatitis B Infection NCT05343481 | Barinthus Biotherapeutics | Phase 2 |
| Unknown | Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients NCT05490836 | Huashan Hospital | N/A |
| Unknown | Prevalence of Significant Liver Fibrosis and Inflammation in Chronic HBV Infected Patients in Grey Zone NCT05483049 | Ruijin Hospital | — |
| Active Not Recruiting | Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entec NCT05423834 | Chinese University of Hong Kong | — |
| Unknown | Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy NCT05792878 | Beijing Ditan Hospital | — |
| Completed | A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients NCT05244057 | Shanghai HEP Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins NCT05345990 | Hannover Medical School | Phase 2 |
| Completed | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic H NCT05414981 | Assembly Biosciences | Phase 1 |
| Completed | A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers NCT06311734 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT. NCT05797714 | Ruijin Hospital | N/A |
| Recruiting | Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD NCT05766449 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Completed | A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers NCT05273775 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients NCT06295328 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 / Phase 2 |
| Terminated | A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in NCT05238844 | Antios Therapeutics, Inc | Phase 2 |
| Completed | Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Pat NCT07175688 | Tanta University | — |
| Unknown | Performance of Novel Simplified Score for Chronic Hepatitis B Treatment Eligibility in Thailand NCT05295914 | Mahidol University | — |
| Terminated | Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects NCT05298332 | Antios Therapeutics, Inc | Phase 1 |
| Enrolling By Invitation | A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B NCT06707922 | Xiamen Amoytop Biotech Co., Ltd. | N/A |
| Completed | Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects NCT05189288 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Unknown | A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) NCT05808335 | ImmuneMed, Inc. | Phase 2 |
| Active Not Recruiting | Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients NCT05147090 | The University of Hong Kong | Phase 4 |
| Unknown | The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia NCT05357183 | Beijing Ditan Hospital | — |
| Unknown | Disease Loads and Status of Treatment NCT05264272 | National Taiwan University Hospital | — |
| Unknown | The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia NCT05357235 | Beijing Ditan Hospital | — |
| Active Not Recruiting | A Study of LP-128 Capsules in Healthy Subjects NCT05130567 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Completed | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic H NCT04980482 | Arbutus Biopharma Corporation | Phase 2 |
| Completed | A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chro NCT05839639 | Huahui Health | Phase 2 |
| Unknown | Study on Clinical Program Optimization of Inactive Hepatitis B Surface Antigen (HBsAg) Carriers (IHCs) NCT05457920 | Henan Provincial People's Hospital | N/A |
| Completed | Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets NCT06431438 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Terminated | A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Singl NCT05001022 | Aligos Therapeutics | Phase 1 |
| Completed | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Tre NCT04891770 | Gilead Sciences | Phase 2 |
| Completed | A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection NCT05017116 | Suzhou Ribo Life Science Co. Ltd. | Phase 1 |
| Unknown | The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve G NCT04997564 | Peking University First Hospital | Phase 4 |
| Unknown | COIN-B: COntrolled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections NCT04779970 | University Hospital, Antwerp | N/A |
| Unknown | Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of NCT04980664 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Unknown | Safety and Efficacy of TAF to Prevent MTCT of HBV in Middle/Late Pregnancies With High HBV DNA Load NCT05466071 | Xingfei Pan | — |
| Active Not Recruiting | Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection NCT05410496 | Taichung Veterans General Hospital | Phase 4 |
| Active Not Recruiting | Stopping Antiviral Treatment in Chronic Hepatitis B NCT04431245 | The University of Hong Kong | — |
| Terminated | A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis NCT04820686 | Assembly Biosciences | Phase 2 |
| Recruiting | Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women NCT05853718 | First People's Hospital of Hangzhou | Phase 4 |
| Unknown | Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients NCT04864366 | Huashan Hospital | — |
| Unknown | Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B NCT04850950 | The First Affiliated Hospital of Zhengzhou University | Phase 4 |
| Unknown | Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) NCT04939441 | Jidong Jia | Phase 4 |
| Unknown | Plasma Purification and Chronic Hepatitis B NCT04518553 | Shanghai Pudong Hospital | N/A |
| Unknown | Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects NCT04676893 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Terminated | A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infect NCT04781647 | Assembly Biosciences | Phase 2 |
| Completed | Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B NCT04629976 | Nucorion Pharmaceuticals, Inc. | Phase 1 |
| Completed | GLS4/RTV and TAF Drug-drug Interaction NCT04551261 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Unknown | Prevalence of Occult Hepatitis B Virus Infection（OBI） in Subjects With Chronic Hepatitis B（CHB） Family History NCT04672915 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 1 NCT04650828 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | LDT Combined With TDF to Improve EGFR Decreasing in Patients With Chronic Hepatitis B Treated With TDF NCT04643990 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Completed | A Study to Evaluate the Mass Balance Absorption and AME of VBR NCT04637139 | Assembly Biosciences | Phase 1 |
| Terminated | A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection NCT04454567 | Assembly Biosciences | Phase 2 |
| Completed | A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Singl NCT04536337 | Aligos Therapeutics | Phase 1 |
| Active Not Recruiting | Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue NCT04496882 | National Taiwan University Hospital | Phase 4 |
| Recruiting | Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B NCT04896255 | Huashan Hospital | — |
| Unknown | Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study NCT04543565 | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Phase 3 |
| Terminated | A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection NCT04398134 | Assembly Biosciences | Phase 2 |
| Terminated | A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Singl NCT04485663 | Aligos Therapeutics | Phase 1 |
| Unknown | The Efficacy and Safety of TAF vs Other NAs in Patients With LVL NCT04501224 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Unknown | Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection NCT04507607 | Third Affiliated Hospital, Sun Yat-Sen University | EARLY_Phase 1 |
| Completed | Serum Regucalcin Level and Chronic Hepatitis B NCT05435599 | Konya Meram State Hospital | N/A |
| Unknown | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Or NCT04480294 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB NCT04464733 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients NCT04465890 | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 |
| Unknown | Biomarkers Guided Stopping NAs Treatment NCT04519359 | Nanfang Hospital, Southern Medical University | N/A |
| Completed | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Inf NCT04412863 | Vir Biotechnology, Inc. | Phase 2 |
| Completed | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection NCT04423393 | Vir Biotechnology, Inc. | Phase 1 |
| Completed | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults NCT04271592 | Assembly Biosciences | Phase 1 |
| Unknown | The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mi NCT04674423 | National Cheng-Kung University Hospital | Phase 4 |
| Unknown | A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Ci NCT04301908 | Beijing Ditan Hospital | — |
| Unknown | A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir NCT04277897 | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Phase 1 |
| Completed | Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B NCT04182321 | Fu-Sheng Wang | N/A |
| Completed | Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD NCT05523648 | Sichuan Leshan Traditional Chinese Medicine Hospital | EARLY_Phase 1 |
| Unknown | Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) NCT04202653 | Tongji Hospital | Phase 2 |
| Completed | A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B NCT04846491 | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 |
| Unknown | A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B NCT04180150 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients NCT04718831 | Taipei Medical University WanFang Hospital | N/A |
| Completed | Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B NCT03905655 | Romark Laboratories L.C. | Phase 2 |
| Completed | A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Hea NCT04142762 | Assembly Biosciences | Phase 1 |
| Completed | A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults NCT04083716 | Assembly Biosciences | Phase 1 |
| Unknown | An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients Wit NCT04157699 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Unknown | An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patie NCT04157257 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients NCT05671315 | Qing XIe | N/A |
| Active Not Recruiting | Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guide NCT03753074 | Young-Suk Lim | Phase 4 |
| Withdrawn | Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B NCT03575208 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Active Not Recruiting | Halting Nucleoside Analogues in Chronic Hepatitis B NCT04102176 | Seng Gee Lim | N/A |
| Unknown | TAF Real World Study for Universal Effectiveness NCT03752658 | Tongji Hospital | — |
| Completed | Evaluation of Liver Fibrosis With 2D-Shear Wave Elastography NCT04759521 | Seyhmus Kavak | — |
| Unknown | The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg NCT03801538 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b NCT04195074 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Terminated | A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients NCT03780543 | Assembly Biosciences | Phase 2 |
| Completed | Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers NCT03847246 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N/A |
| Recruiting | Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK) NCT03792919 | Humanity & Health Medical Group Limited | Phase 4 |
| Completed | Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB NCT05753280 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients NCT03733652 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Completed | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B NCT03672188 | Vir Biotechnology, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B NCT03714152 | Assembly Biosciences | Phase 1 |
| Unknown | Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase Levels NCT03740789 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients NCT03770624 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disopro NCT05286346 | Samjin Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients NCT04539652 | Chong Kun Dang Pharmaceutical | Phase 4 |
| Completed | Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Vire NCT03615066 | Gilead Sciences | Phase 2 |
| Unknown | A Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B NCT04112147 | Cheng-Chung Wei | Phase 2 |
| Unknown | Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea NCT03559790 | The Catholic University of Korea | — |
| Completed | APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B NCT03585322 | Ascentage Pharma Group Inc. | Phase 1 |
| Active Not Recruiting | Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients NCT03777969 | Beijing Friendship Hospital | — |
| Completed | A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects NCT03662568 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Partici NCT03577171 | Assembly Biosciences | Phase 2 |
| Completed | A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection NCT03576066 | Assembly Biosciences | Phase 2 |
| Completed | Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B NCT04028856 | Beijing Ditan Hospital | — |
| Completed | Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic H NCT03491553 | Gilead Sciences | Phase 2 |
| Completed | A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single NCT03439488 | Alios Biopharma Inc. | Phase 1 |
| Terminated | Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir NCT03434353 | Gilead Sciences | Phase 2 |
| Unknown | A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B NCT03357822 | Tongji Hospital | Phase 4 |
| Completed | Correlation Between Virus and Biochemical Characteristics and Liver Histological Damage in Untreated Chronic H NCT04032275 | Beijing Ditan Hospital | — |
| Unknown | Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B NCT03429439 | Zhongshan Hospital Xiamen University | N/A |
| Completed | Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy NCT05451420 | Henan Provincial People's Hospital | N/A |
| Completed | Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF NCT03356834 | Humanity and Health Research Centre | Phase 4 |
| Unknown | Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hep NCT03349008 | Cttq | Phase 4 |
| Completed | A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovi NCT05282407 | Samjin Pharmaceutical Co., Ltd. | Phase 4 |
| Unknown | The Effect of Entecavir Consolidation on Post-TDF Treatment Durability NCT03308890 | Taipei Veterans General Hospital, Taiwan | Phase 4 |
| Completed | Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. NCT03241641 | Young-Suk Lim | Phase 4 |
| Unknown | Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Pati NCT03448744 | Wen-hong Zhang | Phase 4 |
| Completed | Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal NCT03215732 | ANRS, Emerging Infectious Diseases | — |
| Unknown | The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resect NCT03253250 | Huashan Hospital | Phase 4 |
| Unknown | A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic NCT03244085 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules NCT03638076 | Sunshine Lake Pharma Co., Ltd. | Phase 2 |
| Completed | IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB NCT03734783 | Changhai Hospital | — |
| Completed | Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxi NCT03180619 | Gilead Sciences | Phase 2 |
| Completed | Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B NCT03109730 | Assembly Biosciences | Phase 1 / Phase 2 |
| Unknown | A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo NCT03642340 | IlDong Pharmaceutical Co Ltd | — |
| Unknown | Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients NCT04646928 | CHA University | — |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy NCT03038113 | Hoffmann-La Roche | Phase 1 |
| Terminated | Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir NCT03032536 | Alios Biopharma Inc. | Phase 1 |
| Unknown | The Study of Short-range Antiviral Treatment During Pregnancy to Block Mother-to-child Transmission of Hepatit NCT03209908 | Beijing Ditan Hospital | — |
| Unknown | Efficacy and Adverse Effects of Nucleoside Analogues (TDF/LDT) in Preventing Mother-to-child Transmission of H NCT03181607 | Xingfei Pan | — |
| Unknown | The Incidence of Postpartum Hepatitis in Pregnant Women With Chronic Hepatitis B Virus Infection NCT03214302 | Beijing Ditan Hospital | N/A |
| Completed | Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are NCT02979613 | Gilead Sciences | Phase 3 |
| Unknown | Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B NCT04069858 | Korea University | Phase 4 |
| Recruiting | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infectio NCT02932150 | Gilead Sciences | Phase 2 |
| Completed | A Study in Healthy Volunteers and Patients With Chronic Hepatitis B NCT02908191 | Assembly Biosciences | Phase 1 |
| Unknown | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepa NCT02991638 | The University of Hong Kong | Phase 3 |
| Unknown | Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus NCT02899130 | Composite Interceptive Med Science | N/A |
| Completed | Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regim NCT02862548 | Gilead Sciences | Phase 2 |
| Unknown | Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients NCT02793791 | Shandong Cancer Hospital and Institute | N/A |
| Unknown | A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs NCT02894918 | Henan Provincial People's Hospital | Phase 4 |
| Recruiting | Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease NCT02863757 | Humanity and Health Research Centre | — |
| Unknown | Immune Function Status and the Prevalence of Hepatitis in Postpartum Pregnant Women With CHB Infection NCT02886182 | Beijing Ditan Hospital | — |
| Unknown | HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients NCT02908763 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level NCT02893124 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Terminated | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) NCT02826018 | Alnylam Pharmaceuticals | Phase 1 |
| Unknown | The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg NCT02838810 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Ran NCT02817685 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet NCT02805738 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Unknown | Off-therapy Response After Stopping Entecavir or Tenofovir NCT03042481 | Kaohsiung Medical University Chung-Ho Memorial Hospital | — |
| Unknown | The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg NCT02745704 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B NCT02774837 | Seng Gee Lim | Phase 4 |
| Completed | REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection NCT02565719 | Replicor Inc. | Phase 2 |
| Unknown | Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and NCT02973646 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy NCT03366571 | Beijing Friendship Hospital | — |
| Completed | Off Treatment Durability in Chronic Hepatitis B With Good Immune Control NCT02738554 | The University of Hong Kong | N/A |
| Unknown | Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patien NCT03332329 | Qin Ning | Phase 4 |
| Completed | Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoprox NCT02579382 | Gilead Sciences | Phase 2 |
| Completed | A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients NCT02569372 | Green Cross Corporation | Phase 1 |
| Unknown | A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB NCT02615639 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 1 / Phase 2 |
| Unknown | Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Ther NCT02589652 | Huashan Hospital | — |
| Completed | Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy NCT02594293 | Huashan Hospital | Phase 4 |
| Completed | Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet NCT02589457 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Completed | Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B NCT02533544 | Myeong Jun Song | — |
| Completed | Safety and Tolerability of TG1050: A Dose-finding Study NCT02428400 | Transgene | Phase 1 |
| Recruiting | The Establishment of Korean Hepatitis B Patients Cohort NCT04139850 | Yonsei University | — |
| Terminated | Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus NCT02452528 | Arrowhead Pharmaceuticals | Phase 2 |
| Unknown | A Study of the Interruption on the Mother-to-child Transmission of Hepatitis B Virus （HBV MTCT）in Newborns at NCT02901418 | Beijing Ditan Hospital | — |
| Unknown | Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B NCT02532413 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Completed | Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to T NCT02792088 | IlDong Pharmaceutical Co Ltd | Phase 3 |
| Withdrawn | The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study NCT01831037 | University of Arkansas | — |
| Completed | Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy NCT02505009 | Chang Gung Memorial Hospital | Phase 4 |
| Unknown | An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients NCT02560649 | Ruijin Hospital | Phase 4 |
| Unknown | Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults NCT02822547 | Yonsei University | Phase 4 |
| Completed | Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment NCT02364336 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Withdrawn | Study of ARC-520 in Patient With Chronic Hepatitis B Virus NCT02349126 | Arrowhead Pharmaceuticals | Phase 2 |
| Completed | Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patient NCT02401737 | Novira Therapeutics, Inc. | Phase 1 |
| Completed | A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB NCT01935635 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 1 / Phase 2 |
| Unknown | Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude NCT02523547 | Hanmi Pharmaceutical Company Limited | Phase 4 |
| Unknown | Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B NCT02463019 | E-DA Hospital | Phase 4 |
| Active Not Recruiting | Impact of Fatty Liver on Hepatitis B Therapy NCT06535048 | Tianjin Second People's Hospital | — |
| Terminated | Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic He NCT02258581 | Gilead Sciences | — |
| Completed | Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B NCT02249988 | Abivax S.A. | Phase 2 / Phase 3 |
| Completed | Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients Wi NCT02355951 | Transgene | N/A |
| Completed | Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers NCT02300688 | IlDong Pharmaceutical Co Ltd | Phase 1 |
| Terminated | Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents Wit NCT02058108 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B NCT02263755 | Yonsei University | — |
| Unknown | Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B NCT02287857 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N/A |
| Unknown | Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients NCT02474316 | Ruijin Hospital | Phase 4 |
| Completed | Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Pa NCT02174276 | Gilead Sciences | Phase 2 |
| Withdrawn | Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background NCT02053727 | University of California, Los Angeles | N/A |
| Completed | Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally NCT02166047 | Gilead Sciences | Phase 2 |